Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease of the motor system in which both upper motor neurons in the cortex and lower motor neurons in the brainstem and spinal cord degenerate. The result is progressive weakness, muscle wasting, spasticity, and difficulty with speech, swallowing, and ultimately breathing, with a course that is usually relentless.

Definition

Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder defined by the combined degeneration of upper and lower motor neurons, producing progressive muscle weakness, atrophy, and spasticity; most cases show TDP-43 pathology, and it lies on a clinical and pathological continuum with frontotemporal dementia.

Scope

This entry covers the defining feature of combined upper and lower motor neuron degeneration, the clinical syndrome and its bulbar and limb presentations, the molecular pathology (notably TDP-43) and genetics, the overlap with frontotemporal dementia, and diagnostic frameworks. It is a reference overview, not clinical guidance for any individual.

Core questions

• How does combined upper and lower motor neuron loss produce the clinical syndrome?
• What molecular pathology, especially TDP-43, drives motor neuron degeneration?
• What links amyotrophic lateral sclerosis genetically to frontotemporal dementia?
• How is the diagnosis established and distinguished from mimics?

Key concepts

• Upper and lower motor neuron degeneration
• Bulbar-onset and limb-onset presentations
• TDP-43 proteinopathy
• C9orf72, SOD1, and other genetic causes
• Amyotrophic lateral sclerosis-frontotemporal dementia spectrum
• El Escorial / revised diagnostic criteria
• Familial versus sporadic disease

Key theories

TDP-43 proteinopathy of motor neurons

The identification of ubiquitinated TDP-43 as the principal aggregated protein in the great majority of amyotrophic lateral sclerosis cases established the disease as a TDP-43 proteinopathy and tied it mechanistically to frontotemporal lobar degeneration.

Amyotrophic lateral sclerosis-frontotemporal dementia continuum

Shared genetics (notably the C9orf72 repeat expansion) and shared TDP-43 pathology, together with overlapping clinical features in many patients, support viewing amyotrophic lateral sclerosis and frontotemporal dementia as a single disease spectrum rather than wholly separate disorders.

Mechanisms

Amyotrophic lateral sclerosis is characterised by the progressive loss of upper motor neurons in the motor cortex and corticospinal tracts and of lower motor neurons in the brainstem and spinal cord. Upper motor neuron loss produces spasticity and brisk reflexes, while lower motor neuron loss produces weakness, wasting, and fasciculations; the combination in the same regions is the diagnostic signature. The predominant molecular pathology is cytoplasmic aggregation of TDP-43, and a range of genetic causes (most prominently the C9orf72 repeat expansion, as well as SOD1 and others) converge on motor neuron degeneration, with mechanisms implicating impaired RNA processing, proteostasis, and axonal transport. The shared TDP-43 pathology and genetics underlie the overlap with frontotemporal dementia (Feldman et al., 2022; Neumann et al., 2006; Dugger & Dickson, 2017).

Clinical relevance

Amyotrophic lateral sclerosis is the most common adult-onset motor neuron disease, and recognising the combination of upper and lower motor neuron signs is central to how it is identified and distinguished from mimics. Diagnostic criteria such as the revised El Escorial criteria formalise the required pattern of involvement. This entry describes how the disease is understood and classified; it is not a basis for individual diagnostic or treatment decisions.

Epidemiology

Amyotrophic lateral sclerosis is a relatively uncommon disease with onset typically in mid-to-late adult life and a modest male predominance. The majority of cases are sporadic, while a minority are familial; a substantial share of familial and some sporadic cases are attributable to identified genetic causes, most notably the C9orf72 repeat expansion (Feldman et al., 2022).

History

Jean-Martin Charcot delineated amyotrophic lateral sclerosis in the 1860s-1870s, recognising the combined degeneration of upper and lower motor neurons that gives the disease its name. The El Escorial criteria and their later revision (Brooks et al., 2000) standardised diagnosis for research and practice. The identification of TDP-43 as the major aggregating protein (Neumann et al., 2006) and the later discovery of the C9orf72 repeat expansion reframed the disease molecularly and cemented its link to frontotemporal dementia.

Debates

Is amyotrophic lateral sclerosis a single disease or a syndrome with many causes?

The diversity of genetic causes, the variable involvement of cognition, and the spectrum from pure motor disease to frontotemporal dementia have prompted debate over whether amyotrophic lateral sclerosis is one disease or a final common pathway reached by several distinct processes.

Key figures

• Jean-Martin Charcot
• Benjamin Rix Brooks
• Manuela Neumann
• Eva Feldman
• Pamela Shaw

Seminal works

• feldman-2022
• neumann-2006
• brooks-2000

Frequently asked questions

What distinguishes amyotrophic lateral sclerosis from other motor problems?

Its hallmark is the presence of both upper motor neuron signs (such as spasticity and brisk reflexes) and lower motor neuron signs (such as weakness, wasting, and fasciculations) in the same body regions, progressing over time, which is the pattern captured by diagnostic criteria.

Does amyotrophic lateral sclerosis affect thinking?

Although it is primarily a motor disease, a proportion of patients develop cognitive or behavioural changes, and some meet criteria for frontotemporal dementia, reflecting the shared pathology and genetics linking the two conditions.